Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

- - - 37,901

Total revenues 2,046,708 1,954,977 9,663,513 13,709,186

Operating expenses:

Research and

development 8,268,413 8,468,763 36,060,470 35,615,536

General and

administrative 2,820,543 3,372,108 13,569,578 12,254,892

Restructuring

charges 345,426 - 1,563,274 -

Total operating

expenses 11,434,382 11,840,871 51,193,322 47,870,428

Loss from operations (9,387,674) (9,885,894) (41,529,809) (34,161,242)

Interest income 661,381 898,786 2,971,666 3,394,751

Interest expense (57,631) (44,018) (209,885) (477,643)

Other income, net 5,949 1,124 7,108 6,873

Net loss $(8,777,975) $(9,030,002) $(38,760,920) $(31,237,261)

Basic and diluted

loss per share $(0.26) $(0.31) $(1.20) $(1.13)

Shares used in

computing basic and

diluted loss

per share 34,336,645 29,386,886 32,340,203 27,758,348


'/>"/>
SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Nov. 25, 2014  Roka Bioscience, Inc. (NASDAQ: ... testing solutions for the detection of foodborne pathogens, today announced ... Piper Jaffray  26 th Annual Healthcare Conference on December ... at The New York Palace in New York, ... information concerning the Company, its operations, strategies and prospects may ...
(Date:11/24/2014)... 2014 Five American winners will ... Maktoum Awards for Medical Sciences", in its 8 th ... Emirates , on 15 December 2014. ... The Carter Center which won the Hamdan Award for ... numerous programs that aim to improve health and promote ...
(Date:11/24/2014)... , Nov. 24, 2014 VolitionRx Limited ... tests for cancer and other conditions, today announced that data ... the Science for Business BioWin Day 2014, being held November ... data come from VolitionRx,s lung cancer pilot study, the samples ... Centre Hospitalier Universitaire (CHU) de Liege in Belgium ...
(Date:11/24/2014)... 2014   Veracyte, Inc. (Nasdaq: VCYT ... and chief executive officer, will present in a fireside chat ... Conference on Tuesday, December 2, 2014 at 12:30 p.m. ET ... live audio webcast and subsequent replay may be accessed by ... the website at least 15 minutes prior to the live ...
Breaking Biology Technology:Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2Five US Winners Among Recipients of Hamdan Medical Awards 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2
... Breast Cancer Profile Represents First Molecular ... of Operable Breast Cancer, ALISO VIEJO, Calif., Jan. ... technology and services resource for,pathologists, oncologists and the pharmaceutical ... cancer test, the first molecular,test available that is applicable ...
... and Chairman of the Board ... ... care biopharmaceutical company, announced today that,Daniel Tasse has been appointed President and Chief ... CEO since,the creation of Ikaria Holdings in March 2007 and will now serve ...
... Q-MED AB to distribute Palomar products outside North ... Medical,Technologies, Inc. (Nasdaq: PMTI ), a leading ... today announced the execution,of an international distribution agreement ... Stockholm Mid Cap: QMED), a leading,biotech/medical device company ...
Cached Biology Technology:Clarient to Commercialize Novel Breast Cancer Profile 2Clarient to Commercialize Novel Breast Cancer Profile 3Clarient to Commercialize Novel Breast Cancer Profile 4Clarient to Commercialize Novel Breast Cancer Profile 5Ikaria Appoints Daniel Tasse as President and Chief Executive Officer 2Palomar and Q-MED AB Enter Into International Distribution Agreement 2Palomar and Q-MED AB Enter Into International Distribution Agreement 3Palomar and Q-MED AB Enter Into International Distribution Agreement 4Palomar and Q-MED AB Enter Into International Distribution Agreement 5Palomar and Q-MED AB Enter Into International Distribution Agreement 6
(Date:11/3/2014)... , Nov. 3, 2014  NeuroSigma ® , ... life sciences company focused on commercialization of its ... for the treatment of neurological and neuropsychiatric disorders, ... Property has issued a Notice of Allowance for ... is co-owned by NeuroSigma and the Regents of ...
(Date:11/2/2014)... Physics World , James Dacey explores the ways in ... take their innovations from the lab into the commercial ... all start-up companies as they move from prototype to ... main factors: physics-based inventions are usually far from market-ready ... be a lot more complicated than had been originally ...
(Date:11/2/2014)... fascinating to put a flashlight up to our palms ... University in St. Louis engineers are using a similar ... improve imaging of cancerous tissues and to develop potential ... Beare Distinguished Professor of Biomedical Engineering at the School ... time-reversal technology that allows researchers to better focus light ...
Breaking Biology News(10 mins):NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3The 'valley of death' facing physics start-ups 2Improving imaging of cancerous tissues by reversing time 2
... in factory workers producing microwave popcorn might play an ... by people with cystic fibrosis (CF), according to a ... Katrine Whiteson. The molecule, known as 2,3-butanedione or diacetyl, ... than in healthy ones. CF patients experience day-to-day ...
... have long known that people with autoimmune diseases, such ... are at greater risk of developing schizophrenia. ... majority of the Danish population shows that the development ... an increased risk of contracting autoimmune diseases, especially if ...
... COLUMBUS, Ohio Chronic stress that produces inflammation and anxiety ... prolonged fight, causing the animals to have an excessive reaction ... After the mice recovered from the effects of chronic ... them to a chronically stressed state in biological and behavioral ...
Cached Biology News:Is a 'buttery' molecule behind cystic fibrosis flare-ups? 2Is a 'buttery' molecule behind cystic fibrosis flare-ups? 3Schizophrenics are at greater risk of getting diseases 2Schizophrenics are at greater risk of getting diseases 3Study in mice raises question: Could PTSD involve immune response to stress? 2Study in mice raises question: Could PTSD involve immune response to stress? 3Study in mice raises question: Could PTSD involve immune response to stress? 4
... Digital shaking water bath, with a comprehensive ... and shaking water baths with seamless, splash-water ... The bright MULTI-DISPLAY (LED) indicating up to ... the lab. Advanced MICROPROCESSOR technology with PID ...
... an aqueous solution that contains a purified ... in a MOPS buffer (3-(N-Morpholino) propanesulfonic acid), ... contains a combination of 0.02% methylisothiazolone, 0.02% ... and Haas Company) as a preservative. ...
Request Info...
... Life Science FLA-7000 excels at fluorescent and ... documentation. It features four easy-to-access filters (filters ... filter for Imaging Plates) for upgrading flexibility. ... choice of four kinds of excitation laser ...
Biology Products: